title: A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
abstract: OBJECTIVE
  A preliminary study with the aim of evaluating the safety and efficacy of a single intraperitoneal administration of paclitaxel, combined with intravenous administration of paclitaxel plus S-1, was carried out in gastric cancer patients with peritoneal metastasis.
  
  
  METHODS
  Paclitaxel was administered intraperitoneally at 80 mg/m(2). After one to two weeks, S-1 was administered at 80 mg/m(2)/day for 14 consecutive days, followed by seven days' rest. Paclitaxel was administered intravenously at 50 mg/m(2) on days 1 and 8. The safety, pharmacokinetic analysis and efficacy of this therapy were investigated.
  
  
  RESULTS
  Fifteen patients were enrolled in this study. The toxic effects of the intraperitoneal chemotherapy were mild. The toxic effects with the systemic chemotherapy were acceptable. The ratio of (AUC peri)/(AUC pla) was 1065:1 in the pharmacokinetic analysis. The one-year overall survival rate was 10/15 (66.7%).
  
  
  CONCLUSIONS
  A single intraperitoneal administration of paclitaxel combined with intravenous administration of paclitaxel plus S-1 is a well-tolerated and feasible treatment for patients with gastric cancer with peritoneal metastasis.
authors.affiliation: Kinki University Faculty of Medicine, Osaka, Japan. imano@med.kindai.ac.jp
authors.forename: Motohiro
authors.initials: M
authors.lastname: Imano
authors.forename: Ying-Feng
authors.initials: YF
authors.lastname: Peng
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Itoh
authors.forename: Masayasu
authors.initials: M
authors.lastname: Nishikawa
authors.forename: Takao
authors.initials: T
authors.lastname: Satou
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yasuda
authors.forename: Keisuke
authors.initials: K
authors.lastname: Inoue
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kato
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shinkai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsubaki
authors.forename: Takushi
authors.initials: T
authors.lastname: Yasuda
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Imamoto
authors.forename: Shozo
authors.initials: S
authors.lastname: Nishida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Takeyama
authors.forename: Kiyokata
authors.initials: K
authors.lastname: Okuno
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Shiozaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel